Its undoubtably a problematic device. It can support a sick heart but if the heart is too weak the sick heart will win. Having said that nobly really knows when a heart is too sick. Look at Emmet? sleeping on his knees to full recovery. Nice to use C-Pulse as a step between drugs and VADs but again when is someone too sick, when is C-Pulse advantageous enough. Is fibrous growth more than a nuisance? Co-morbidities for some it would be plain for others not so plain. Do driveline infections limit efficacy. Then lugging around a C-Pulse controller which gives relief is far better than lugging around an oxygen bottle which doesn't work, On this criteria every Class 3 should have one but would governments foot the bill? So an efficacy standard of reduced hospitalisations and life exspectancy is used, but is this really appropriate?
For an investor HF is just littered with failure.
Another one has just been recently pointed out to me. http://www.reuters.com/article/2015/07/27/us-bellerophon-study-idUSKCN0Q112820150727
Another variant of the (pretty well discredited) "net" idea to stop enlargement.
Interim analysis says C-Pulse is the right side of the success curve but it can't be taken for granted.
I think we are travelling well, every time there is a problem, management go down to the basement and fix it bottom up and SSH moves marginally forward. Long exhausting process, but the right one.
If you want to get out of HF C-Pulse is the only viable bus at this stage.
SHC Price at posting:
2.5¢ Sentiment: Buy Disclosure: Not Held
